Mechanisms of human autoimmunity

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2228-2233

  Rosenblum, Michael D ^a   Remedios, Kelly A ^a   Abbas, Abul K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ALLELE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; ENVIRONMENTAL FACTOR; GENE DELETION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HLA SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; ADVERSE EFFECTS; ANIMAL; ENVIRONMENTAL EXPOSURE; IMMUNOLOGY; LYMPHOCYTE; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; ENVIRONMENTAL EXPOSURE; HUMANS; LYMPHOCYTES;

EID: 84930408029     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78088     Document Type: Article

References (57)

1. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010;6(3): 165-174.
2. Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108(12): 1835-1842.
3. Zenewicz LA, Abraham C, Flavell RA, Cho JH. Unraveling the genetics of autoimmunity. Cell. 2010;140(6): 791-797.
4. Hafler D, Housley W, Marson A. Genetics of autoimmunity. J Clin Invest. 2015;125(6): 2234-2241.
5. Goris A, Liston A. The immunogenetic architecture of autoimmune disease. Cold Spring Harb Perspect Biol. 2012;4(3): A007260.
6. Liblau R, et al. T cell response to myelin basic protein epitopes in multiple sclerosis patients and healthy subjects. Eur J Immunol. 1991;21(6): 1391-1395.
7. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 1990;346(6280): 183-187.
8. Ghoreschi K, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature. 2010;467(7318): 967-971.
9. Vandenbroeck K. Cytokine gene polymorphisms and human autoimmune disease in the era of genome-wide association studies. J Interferon Cytokine Res. 2012;32(4): 139-151.
10. Elliott M, et al. Ustekinumab: Lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci. 2009;1182: 97-110.
11. Papp KA, et al. Brodalumab, an anti-interleukin- 17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13): 1181-1189.
12. Bennett CL, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27(1): 20-21.
13. Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zincfinger domains. Nat Genet. 1997;17(4): 399-403.
14. Fisher GH, et al. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6): 935-946.
15. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol. 2011;11(12): 807-822.
16. Root-Bernstein R, Fairweather D. Complexities in the relationship between infection and autoimmunity. Curr Allergy Asthma Rep. 2014;14(1): 407.
17. Serafini B, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204(12): 2899-2912.
18. Mikuls TR, et al. Periodontitis and porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(5): 1090-1100.
19. Ochoa-Repáraz J, et al. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. J Immunol. 2010;185(7): 4101-4108.
20. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1): 121-141.
21. Mathis D, Benoist C. Microbiota and autoimmune disease: The hosted self. Cell Host Microbe. 2011;10(4): 297-301.
22. Kuhn A, Wenzel J, Weyd H. Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: A critical review. Clin Rev Allergy Immunol. 2014;47(2): 148-162.
23. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000;191(3): 411-416.
24. Yurasov S, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201(5): 703-711.
25. Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: Past challenges, future prospects. J Clin Immunol. 2008;28(6): 677-684.
26. Mohan JF, Unanue ER. Unconventional recognition of peptides by T cells and the implications for autoimmunity. Nat Rev Immunol. 2012;12(10): 721-728.
27. Mohan JF, Petzold SJ, Unanue ER. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med. 2011;208(12): 2375-2383.
28. Mohan JF, Levisetti MG, Calderon B, Herzog JW, Petzold SJ, Unanue ER. Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat Immunol. 2010;11(4): 350-354.
29. Kawasaki T, Kawai T, Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol Rev. 2011;243(1): 61-73.
30. Turer EE, et al. Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. J Exp Med. 2008;205(2): 451-464.
31. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312(5780): 1669-1672.
32. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-A. J Exp Med. 2004;199(5): 731-736.
33. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006;25(3): 383-392.
34. Papoutsaki M, Costanzo A. Treatment of psoriasis and psoriatic arthritis. BioDrugs. 2013;27(suppl 1): 3-12.
35. Taylor PC, Feldmann M. Anti-TNF biologic agents: Still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10): 578-582.
36. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol. 2011;25(4): 549-567.
37. Baeten D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906): 1705-1713.
38. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(suppl 2): Ii116-ii123.
39. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10(12): 849-859.
40. Miyara M, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol. 2005;175(12): 8392-8400.
41. Kukreja A, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002;109(1): 131-140.
42. Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. 2011;131(9): 1853-1860.
43. Sanchez Rodriguez R, et al. Memory regulatory T cells reside in human skin. J Clin Invest. 2014;124(3): 1027-1036.
44. Tang Q, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28(5): 687-697.
45. Zhang X. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol. 2004;16(2): 249-256.
46. Rosenblum MD, Gratz IK, Paw JS, Lee K, Marshak- Rothstein A, Abbas AK. Response to self antigen imprints regulatory memory in tissues. Nature. 2011;480(7378): 538-542.
47. Saadoun D, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22): 2067-2077.
48. Castela E, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150(7): 748-751.
49. Koreth J, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22): 2055-2066.
50. Di Ianni M, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14): 3921-3928.
51. Smigiel KS, et al. CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. J Exp Med. 2014;211(1): 121-136.
52. Smigiel KS, Srivastava S, Stolley JM, Campbell DJ. Regulatory T-cell homeostasis: Steady-state maintenance and modulation during inflammation. Immunol Rev. 2014;259(1): 40-59.
53. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med. 2005;202(10): 1375-1386.
54. Kuehn HS, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204): 1623-1627.
55. Schubert D, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12): 1410-1416.
56. Jovanovic V, Dai X, Lim YT, Kemeny DM, MacAry PA. Fc? receptor biology and systemic lupus erythematosus. Int J Rheum Dis. 2009;12(4): 293-298.
57. Dörner T, Shock A, Smith KGC. CD22 and autoimmune disease. Int Rev Immunol. 2012;31(5): 363-378.